StockData
Impact BioMedical Inc. logo

Impact BioMedical Inc. (IBO) stock

IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $329.93MP/E –Yield –

Impact BioMedical operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Impact BioMedical's operating income for the twelve months ending Jun 30, 2026 was -$5.11M. For fiscal 2025 it was -$4.28M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.28M–
FY2024Dec 31, 2024-$28.75M–
FY2023Dec 31, 2023-$4.03M–
FY2022Dec 31, 2022-$3.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$702.00K–
Q1 FY2026Mar 31, 2026-$2.29M–
Q4 FY2025Dec 31, 2025-$1.17M–
Q3 FY2025Sep 30, 2025-$948.00K–
Q2 FY2025Jun 30, 2025-$1.15M–
Q1 FY2025Mar 31, 2025-$1.01M–
Q4 FY2024Dec 31, 2024-$26.23M–
Q3 FY2024Sep 30, 2024-$1.13M–
Q2 FY2024Jun 30, 2024-$626.00K–
Q1 FY2024Mar 31, 2024-$771.00K–
Q4 FY2023Dec 31, 2023-$1.14M–
Q3 FY2023Sep 30, 2023-$1.08M–
Q2 FY2023Jun 30, 2023-$1.01M–
Q1 FY2023Mar 31, 2023-$803.00K–
Q4 FY2022Dec 31, 2022-$1.03M–
Q3 FY2022Sep 30, 2022-$889.00K–
Q2 FY2022Jun 30, 2022-$750.00K–

More Impact BioMedical figures

See a number that looks wrong?